EGFR and prostate carcinoma: The same phenotypic changes could be induced by selecting for resistance to docetaxel in the sensitive prostate cancer cell line DU145 (Puhr et al, 2012) and to the EGFR inhibitor Tarceva in the sensitive lung cancer line H358 (Fig1A).